Moving the needle for oncology dose optimization: A call for action

CPT Pharmacometrics & Systems Pharmacology, vol. 13, pp. 909–918

Abstract

Moving the needle

Authors 6

1. Karthik Venkatakrishnan corresponding

   EMD Serono, Inc. (United States) · Merck Healthcare KGaA, Darmstadt (Germany)

   Affiliation as printed

   EMD Serono Research and Development Institute, Inc. Billerica Massachusetts USA

   EMD Serono Research and Development Institute, Inc., Billerica, Massachusetts, USA

2. Priya Jayachandran

   Regeneron (United States)

   Affiliation as printed

   Regeneron Pharmaceuticals, Inc. Tarrytown New York USA

   Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA

3. Shirley K. Seo

   United States Food and Drug Administration · Center for Drug Evaluation and Research

   Affiliation as printed

   Division of Cardiometabolic and Endocrine Pharmacology Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration Silver Spring Maryland USA

   Division of Cardiometabolic and Endocrine Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

   This publication reflects the views of the author and should not be construed to represent FDA's views or policies

4. Piet H. van der Graaf Aachen

   Leiden University

   Affiliation as printed

   Certara Canterbury UK

   Leiden University Leiden The Netherlands

   Certara, Canterbury, UK

   Leiden University, Leiden, The Netherlands

5. John A. Wagner
   Affiliation as printed

   Koneksa Health New York New York USA

   Koneksa Health, New York, New York, USA

6. Neeraj Gupta corresponding
   Affiliation as printed

   Takeda Pharmaceuticals Cambridge Massachusetts USA

   Takeda Pharmaceuticals, Cambridge, Massachusetts, USA